Eric Rowinsky, MD
Dr. Rowinsky brings over 25 years of experience in cancer research to the SapVax team. He has been responsible for clinical development and registration of several breakthrough oncology agents such as Erbitux for ovary, breast, and other malignancies, and Hycamptin for ovarian cancer.
Dr. Rowinsky holds various roles in addition to his work with SapVax. He is the Chief Scientific Officer of Oncology for Clearpath Development Company, an organization partnering with leading biopharmaceutical companies to expand early product pipeline opportunities and minimize financial impact. He is the Executive Chairman of RGenix, Inc., and holds positions on the Board of Directors for companies including Biogen, Inc., Navidea, and Fortress Biotech. Dr. Rowinsky is also an Adjunct Professor of Medicine at the New York School of Medicine and is a Cancer Drug Development Consultant for Oncodrugs.
Dr. Rowinsky received his M.D. at Vanderbilt University School of Medicine and completed his residency in Internal Medicine at the University of California, San Diego – School of Medicine.